Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Seeking Alpha
Cameron Turtle - CEO & Director Sheldon Sloan - Chief Medical Officer Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Presentation Thomas Smith Leerink Partners LLC, Research Division Good morning, everyone. Thanks for joining us here at the Leerink Partners Global Healthcare Conference. My name is Tom Smith. I'm one of the senior biotech analysts here at Leerink. And it's my pleasure to introduce our next company, Spyre Therapeutics and their management team led by CEO, Cameron Turtle; and CMO, Sheldon Sloan. Gentlemen, thanks for joining us. Cameron Turtle CEO & Director Thanks for having us. Thomas Smith Leerink Partners LLC, Research Division And this is one of our top picks for 2026. We think this company is really best positioned to capitalize on the emergence of combination therapies in inflammatory bowel disease. And we also see the potential for TL1A to be a potential game changer in rheumatology indications. Spyr
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (SYRE) had its "buy" rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 [Yahoo! Finance]Yahoo! Finance
- Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026GlobeNewswire
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
- Spyre Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 3/5/26 - Form EFFECT
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- SYRE's page on the SEC website